At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PRCT PROCEPT BioRobotics
Pre-Mkt 02-11 06:31:03 EST
29.95
+0.74
+2.53%
High30.02Low29.12Vol1.03M
Open29.70D1 Closing29.21Amplitude3.08%
Mkt Cap1.67BTradable Cap1.60BTotal Shares55.88M
T/O30.61MT/O Rate1.92%Tradable Shares53.56M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Procept Biorobotics präsentiert sich auf bedeutenden Gesundheitskonferenzen
Reuters  ·  02-05
Procept Biorobotics präsentiert sich auf bedeutenden Gesundheitskonferenzen
BTIG Sticks to Its Hold Rating for PROCEPT BioRobotics (PRCT)
TIPRANKS  ·  01-27
BTIG Sticks to Its Hold Rating for PROCEPT BioRobotics (PRCT)
Procept Biorobotics Corporation published an update to their financial calendar
Reuters  ·  01-27
Procept Biorobotics Corporation published an update to their financial calendar
PROCEPT BioRobotics® to Host 4Q25 Earnings Conference Call on February 24, 2026, and Investor Day on February 25, 2026, in New York City
GlobeNewswire  ·  01-27
PROCEPT BioRobotics® to Host 4Q25 Earnings Conference Call on February 24, 2026, and Investor Day on February 25, 2026, in New York City
Assessing PROCEPT BioRobotics (PRCT) Valuation As Fresh Analyst Downgrade Meets Confident Long-Term Growth Views
Simply Wall St.  ·  01-11
Assessing PROCEPT BioRobotics (PRCT) Valuation As Fresh Analyst Downgrade Meets Confident Long-Term Growth Views
How Investors Are Reacting To PROCEPT BioRobotics (PRCT) UBS Coverage Initiation And 2027 Profitability Outlook
Simply Wall St.  ·  2025-12-25
How Investors Are Reacting To PROCEPT BioRobotics (PRCT) UBS Coverage Initiation And 2027 Profitability Outlook
PROCEPT BioRobotics Is Maintained at Buy by Truist Securities
Dow Jones  ·  2025-12-19
PROCEPT BioRobotics Is Maintained at Buy by Truist Securities
Truist Securities Adjusts Price Target on PROCEPT BioRobotics to $47 From $50, Maintains Buy Rating
MT Newswires Live  ·  2025-12-18
Truist Securities Adjusts Price Target on PROCEPT BioRobotics to $47 From $50, Maintains Buy Rating
PROCEPT BioRobotics Initiated at Buy by UBS
Dow Jones  ·  2025-12-13
PROCEPT BioRobotics Initiated at Buy by UBS
Sector Update: Health Care Stocks Lower in Afternoon Trading
MT Newswires Live  ·  2025-12-09
Sector Update: Health Care Stocks Lower in Afternoon Trading
PROCEPT BioRobotics has Large Market Opportunity, but Utilization Growth has Slowed, BofA Says
MT Newswires Live  ·  2025-12-09
PROCEPT BioRobotics has Large Market Opportunity, but Utilization Growth has Slowed, BofA Says
Procept Biorobotics Corp : Bofa Global Research Cuts to Neutral From Buy; Cuts Price Objective to $38 From $55
THOMSON REUTERS  ·  2025-12-08
Procept Biorobotics Corp : Bofa Global Research Cuts to Neutral From Buy; Cuts Price Objective to $38 From $55
PROCEPT BioRobotics Cut to Neutral From Buy by B of A Securities
Dow Jones  ·  2025-12-08
PROCEPT BioRobotics Cut to Neutral From Buy by B of A Securities
PROCEPT BioRobotics Is Maintained at Overweight by Morgan Stanley
Dow Jones  ·  2025-12-03
PROCEPT BioRobotics Is Maintained at Overweight by Morgan Stanley
PROCEPT BioRobotics® to Present at Upcoming 37th Annual Piper Sandler Healthcare Conference on December 2, 2025
GlobeNewswire  ·  2025-11-21
PROCEPT BioRobotics® to Present at Upcoming 37th Annual Piper Sandler Healthcare Conference on December 2, 2025
Procept Biorobotics Showcases Aquablation Therapy as Next-Generation BPH Solution in Investor Presentation
Reuters  ·  2025-11-11
Procept Biorobotics Showcases Aquablation Therapy as Next-Generation BPH Solution in Investor Presentation
Analysts’ Opinions Are Mixed on These Healthcare Stocks: PROCEPT BioRobotics (PRCT), Day One Biopharmaceuticals (DAWN) and Exelixis (EXEL)
TIPRANKS  ·  2025-11-06
Analysts’ Opinions Are Mixed on These Healthcare Stocks: PROCEPT BioRobotics (PRCT), Day One Biopharmaceuticals (DAWN) and Exelixis (EXEL)
PROCEPT BioRobotics Price Target Cut to $50.00/Share From $55.00 by Piper Sandler
Dow Jones  ·  2025-11-06
PROCEPT BioRobotics Price Target Cut to $50.00/Share From $55.00 by Piper Sandler
Stock Track | PROCEPT BioRobotics Plummets 7.71% as 2026 Revenue Guidance Disappoints Despite Q3 Beat
Stock Track  ·  2025-11-05
Stock Track | PROCEPT BioRobotics Plummets 7.71% as 2026 Revenue Guidance Disappoints Despite Q3 Beat
PROCEPT BioRobotics Is Maintained at Overweight by Wells Fargo
Dow Jones  ·  2025-11-05
PROCEPT BioRobotics Is Maintained at Overweight by Wells Fargo

Introduction

Company Name.
PROCEPT BioRobotics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
Issue price:
--